Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
First Claim
Patent Images
1. A method for treating migraine in a human patient, comprising the steps of:
- a. Providing an intracutaneous delivery system, comprising;
i. a disposable patch assembly having a plurality of microprojections disposed in an array of about 3 cm2 to about 6 cm2, the array having a density of about 200 to about 2000 microprojections/cm2, the microprojections adapted to penetrate or pierce the stratum corneum of a human patient,ii. the microprojections having a solid formulation coating disposed thereon, wherein the coating comprises zolmitriptan or a pharmaceutically acceptable salt thereof in an amount greater than about 0.6 mg/cm2 to less than about 1 mg/cm2,iii. the microprojections having a width of about 10 μ
m to about 500 μ
m and a tip angle of about 30 to about 70 degrees, andiv. wherein at least 95% of the zolmitriptan is released from the system within about 5 minutes when measured by USP Paddle Over Disk Method (Apparatus
5); and
b. applying the microprojections to a selected area of skin of the patient,wherein the patient has pain freedom at about 2 hours post-application, andwherein the Tmax of a therapeutically effective blood plasma concentration of zolmitriptan occurs within about 30 minutes of the application, the Cmax is about 5 to about 25 ng/ml and the AUC0-2 hr is about 5 to about 20 ng/ml*hour.
3 Assignments
0 Petitions
Accused Products
Abstract
Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods and apparatuses for delivery of zolmitriptan for achieving a Tmax as quick as 2 minutes and not later than 30 minutes in the majority of subjects.
46 Citations
42 Claims
-
1. A method for treating migraine in a human patient, comprising the steps of:
-
a. Providing an intracutaneous delivery system, comprising; i. a disposable patch assembly having a plurality of microprojections disposed in an array of about 3 cm2 to about 6 cm2, the array having a density of about 200 to about 2000 microprojections/cm2, the microprojections adapted to penetrate or pierce the stratum corneum of a human patient, ii. the microprojections having a solid formulation coating disposed thereon, wherein the coating comprises zolmitriptan or a pharmaceutically acceptable salt thereof in an amount greater than about 0.6 mg/cm2 to less than about 1 mg/cm2, iii. the microprojections having a width of about 10 μ
m to about 500 μ
m and a tip angle of about 30 to about 70 degrees, andiv. wherein at least 95% of the zolmitriptan is released from the system within about 5 minutes when measured by USP Paddle Over Disk Method (Apparatus
5); andb. applying the microprojections to a selected area of skin of the patient, wherein the patient has pain freedom at about 2 hours post-application, and wherein the Tmax of a therapeutically effective blood plasma concentration of zolmitriptan occurs within about 30 minutes of the application, the Cmax is about 5 to about 25 ng/ml and the AUC0-2 hr is about 5 to about 20 ng/ml*hour. - View Dependent Claims (2, 3, 4, 13, 22, 23, 24, 25, 27, 28, 29, 30, 31, 34, 37, 40)
-
-
5. A method of treating migraine in a population of human patients in need thereof, comprising the steps of:
-
a. Providing an intracutaneous delivery system, comprising; i. a disposable patch assembly having a plurality of microprojections disposed in an array of about 3 cm2 to about 6 cm2, the array having a density of about 200 to about 800 microprojections/cm2, the microprojections adapted to penetrate or pierce the stratum corneum of a human patient and having a length of about 300 μ
m to about 400 μ
m, a thickness of about 5 μ
m to about 50 μ
m, a width of about 100 μ
m to about 200 μ
m, and are configured at a tip angle of about 30 to about 70 degrees,ii. the microprojections having a solid formulation coating disposed thereon, wherein the coating comprises zolmitriptan or a pharmaceutically acceptable salt thereof in an amount greater than about 0.6 mg/cm2 to less than about 1 mg/cm2, and iii. wherein at least 95% of the zolmitriptan is released from the system within about 5 minutes when measured by USP Paddle Over Disk Method (Apparatus
5); andb. applying the microprojections to a selected area of skin of each patient, wherein more than about 15% of the patients experience pain freedom at about 1 hour post-application, and wherein the Tmax of a therapeutically effective blood plasma concentration of zolmitriptan occurs within about 30 minutes of the application. - View Dependent Claims (6, 7, 8, 9, 10, 11, 32, 35, 38, 41)
-
-
12. A method for treatment or alleviation of migraine or cluster headache in a human patient in need thereof, comprising the steps of:
-
a. Providing an intracutaneous delivery system, comprising; i. a disposable patch assembly having an array of a plurality of microprojections disposed in an array of about 2 cm2 to about 6 cm2 at a density of about 200 to about 800 microprojections/cm2, the microprojections adapted to penetrate or pierce the stratum corneum of the patient, ii. the microprojections having a solid formulation coating disposed thereon, wherein the coating comprises zolmitriptan or a pharmaceutically acceptable salt thereof in an amount greater than about 0.6 mg/cm2 to less than about 1 mg/cm2, iii. the microprojections having a width of about 10 μ
m to about 500 μ
m, a thickness of about 5 μ
m to about 50 μ
m, and at a tip angle of about 30 to about 70 degrees,iv. wherein at least 95% of the zolmitriptan is released from the system within about 5 minutes when measured by USP Paddle Over Disk Method (Apparatus
5), andvi. an impact applicator; and b. applying the patch assembly to a selected area of skin of the patient with the applicator at an energy density of at least 0.05 joules per cm2 in 10 milliseconds or less; wherein the plasma zolmitriptan AUC for the first 2 hours is greater than the plasma zolmitriptan AUC following oral administration of an equivalent dose of zolmitriptan, but the plasma zolmitriptan AUC0-inf following the intracutaneous administration is less than the plasma zolmitriptan AUC0-inf observed after the oral administration of an equivalent dose of zolmitriptan; and wherein the system is configured to deliver a plasma concentration of zolmitriptan of at least 2.0 ng/mL within 15 minutes after application. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21, 26, 33, 36, 39, 42)
-
Specification